NF2 and neoplasm: CROS, BiCROS, BAHS, CI, and ABI are all feasible options in patients with sporadic VS and NF2 when appropriately selected to address the severity, type of patient’s hearing loss, and integrity of the cochlear nerve after tumor resection (Table 1).